Deutsche Bank cuts Schott Pharma stock rating, raises target to EUR 25.00

Published on 10/15/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Deutsche Bank cut its rating and raised its target to EUR 25.00 on October 9, 2026. Schott Pharma stock costs EUR 24.28 versus EUR 24.50.

Deutsche Bank changes its stance

Deutsche Bank raised its Schott Pharma target to EUR 25.00 on October 9, 2026.
Revenue reached EUR 281.76 million in the third quarter of fiscal 2026.
Schott Pharma stock trades at EUR 24.28 at 1:41 p.m. CEST at Lang & Schwarz on October 15, 2026, 0.90 percent below the Xetra close of October 14, 2026.
The next quarterly results are scheduled for December 10, 2026.

Aquarellmalerei eines Glasfabrik-Standorts an einem Fluss in Deutschland — SCHOTT Pharma (DE000A3ENQ51) präsentiert einen Glasfabrik-Campus am Fluss in sanfter Aquarell-Malerei mit fernem Kirchturm, Illustration mit AI erstellt.

Schott Pharma stock (ISIN DE000A3ENQ51) trades at EUR 24.28 at Lang & Schwarz on October 15, 2026, at 1:41 p.m. CEST, 0.90 percent below the Xetra close of October 14, 2026 at EUR 24.50. The latest company-specific catalyst was Deutsche Bank Research's October 9, 2026 downgrade from Buy to Hold while raising its price target from EUR 23.00 to EUR 25.00, according to wallstreetONLINE.

Three target changes shaped the year

The chronology shows how expectations moved. On September 15, 2026, JPMorgan began coverage with an Overweight rating and a EUR 27.10 target, as reported by Finanznachrichten. On October 5, 2026, third-quarter revenue was reported at EUR 281.76 million and fiscal 2026 EBITDA margin guidance stood at 27 percent to 28 percent. On October 9, Deutsche Bank cut its rating but lifted its target to EUR 25.00.

What does the target change mean?

The EUR 25.00 target sits 2.97 percent above the Lang & Schwarz price of EUR 24.28. Deutsche Bank's reasoning combined operational progress with limited valuation room after a strong year-to-date advance, according to the October 9 report. Investing.com also reported a EUR 15.00 million one-off payment in fiscal 2026 and an organic growth estimate of 5.5 percent against a broader consensus of 7 percent.

Next dates bring the next test

The next company events are dated. SCHOTT Pharma lists a BNP Midcap CEO Conference for November 17, 2026 and a LBBW German Company Day for November 18, 2026 on its SCHOTT Pharma investor-relations page. The next quarterly results are expected on December 10, 2026, according to finanzen.net.

Revenue growth meets valuation caution

The third-quarter revenue figure of EUR 281.76 million exceeded the EUR 256.46 million reported for the prior-year quarter, a year-over-year increase of 9.87 percent. Adjusted? The published figure is reported revenue, while earnings per share came in at EUR 0.26 versus EUR 0.30 in the prior-year quarter. For investors, the contrast is clear: sales growth remains measurable, but the latest rating change puts valuation and the next margin update at the center of the stock story.

Stock price and valuation

SCHOTT Pharma AG & Co. KGaA has a market capitalization of EUR 3.7 billion and a 52-week range of EUR 12.62 to EUR 26.05 as of October 15, 2026. The share was trading at EUR 24.28 at Lang & Schwarz on October 15, 2026 at 1:41 p.m. CEST, 0.90 percent below the Xetra close of October 14, 2026 at EUR 24.50. The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.